Bausch + Lomb Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bausch + Lomb Inc.
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
Plus deals involving ASLAN/Zenyaku Kogyo, AstraZeneca/Cholsegen, Astellas/Cullgen, AbCellera/Confo, Blue Water/WraSer, Solve/Cereius, Prime Medicine/Cimeio, Evox/Codiak, PharmaTher/Vitruvias and Adverum/Ray.
Oncology's surprisingly low numbers this year are among the latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Other Names / Subsidiaries
- Bausch & Lomb
- Bausch + Lomb Technolas
- ISTA Pharmaceuticals, Inc. (ISTA)
- Laboratorio Pförtner Cornealent SACIF, Waicon
- Technolas Perfect Vision GmbH
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.